{"id":"fondaparinux-ufh-indicated","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fondaparinux is a synthetic pentasaccharide that binds to antithrombin III, potentiating its inhibition of Factor Xa. By blocking Factor Xa activity, it interrupts the intrinsic and common pathways of the coagulation cascade, preventing the amplification phase of thrombin generation. This results in anticoagulation without direct thrombin inhibition, distinguishing it from unfractionated heparin (UFH) which inhibits both Factor Xa and thrombin.","oneSentence":"Fondaparinux selectively inhibits Factor Xa, a key enzyme in the coagulation cascade, preventing thrombin generation and blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:20.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction)"},{"name":"Venous thromboembolism prophylaxis in orthopedic surgery patients"},{"name":"Treatment of acute deep vein thrombosis and pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT00790907","phase":"PHASE4","title":"Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Acute Coronary Syndrome","enrollment":3235},{"nctId":"NCT00064428","phase":"PHASE3","title":"OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Thromboembolism","enrollment":12092}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fondaparinux - UFH indicated","genericName":"Fondaparinux - UFH indicated","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fondaparinux selectively inhibits Factor Xa, a key enzyme in the coagulation cascade, preventing thrombin generation and blood clot formation. Used for Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction), Venous thromboembolism prophylaxis in orthopedic surgery patients, Treatment of acute deep vein thrombosis and pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}